Antimicrobial resistance in Gram-negative hospital isolates: Results of the Turkish HITIT-2 surveillance study of 2007

Journal of Chemotherapy

Volumn 21, Issue 4, 2009, Pages 383-389

  Gur, Deniz ^a   Hascelik, G ^a   Aydin, N ^b   Telli, M ^b   Gultekin M ^c   Ogunc D ^c   Arikan, O A ^d   Uysal, S ^d   Yaman, A ^e   Kibar, F ^e   Gulay Z ^f   Sumerkan, B ^g   Esel, D ^g   Kayacan, C B ^h   Aktas, Z ^h   Soyletir, G ⁱ   Altinkanat, G ⁱ   Durupinar, B ^j   Darka, O ^j   Akgun Y ^k   Yayla, B ^k   Gedikoglu, S ^l   Sinirtas, M ^l   Berktas, M ^m   Yaman, G ^m   more..

^a HACETTEPE UNIVERSITY   (Turkey)

^b ADNAN MENDERES UNIVERSITY   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

^e CUKUROVA UNIVERSITY   (Turkey)

^f DOKUZ EYLUL UNIVERSITY   (Turkey)

^g ERCIYES UNIVERSITY   (Turkey)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ MARMARA UNIVERSITY   (Turkey)

^j ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^k ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^l ULUDAG UNIVERSITY   (Turkey)

^m YUZUNCU YIL UNIVERSITY   (Turkey)

more..

Author keywords

A. Baumannii; Antimicrobial resistance; E.coli; ESBL; Gram negative bacteria; K. Pneumoniae; P. Aeruginosa; lactamase inhibitor

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD; CEREBROSPINAL FLUID; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HOSPITAL PATIENT; KLEBSIELLA PNEUMONIAE; LUNG LAVAGE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; URINE;

EID: 70349210187     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.4.383     Document Type: Article

References (30)

1. Paterson DL, Ko WC, Gottberg AV, Casellas JM, Mulazimoglu L, Klugman K, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing Extended-Spectrum β-Lactamases: implications for the Clinical Microbiology Laboratory. J Clin Microbiol 2001; 39: 2206-2212.
2. Livermore DM. Bacterial resistance: Origins, epidemiology and impact. Clin Infect Dis 2003; 36(Suppl 1): 11-23.
3. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
4. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control. 2006; 34(5 Suppl 1):S3-10.
5. Masterton RG. Surveillance studies:how can they help the management of infection? J Antimicrob Chemother 2000; 46: 53-58.
6. Lewis D. Antimicrobial resistance surveillance: methods will depend on objectives. J Antimicrob Chemother 2002; 49: 3-5. (Pubitemid 34100639)
7. Morris AK, Masterton RG. Antibiotic resistance surveillance: action for international studies. J Antimicrob Chemother 2002; 49: 7-10.
8. Gür D, Gülay Z, Arikan Akan O, et al. Resistance to newer β-lactams and related ESBL types in gram negative nosocomial isolates in Turkish hospitals- results of the multicenter HITIT study. Turk Mikrobiyol Bult 2008; 42(4): 537-544.
9. Clinical and Laboratory Standards Institute/NCCLS. Performance Standards for Antimicrobial Susceptibility Testing-Seventeenth Informational Supplement. CLSI/NCCLS document M100-S17. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA, 2007.
10. Barry AL, Jones RN and The Collaborative Antimicrobial Susceptibility Testing Group. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J Clin Microbiol 1988; 26: 13-17.
11. Bax R, Bywater R, Comaglia G, Goossens H, Hunter P Isham V, et al. Surveillance of antimicrobial resistance-what, how and whither? Clin Microbiol Infect 2001; 7: 316-325.
12. Över U, Gür D, Ünal S, Miller GH, Aminoglycoside Resistance Study Group. The changing nature of aminoglycoside resistance mechanisms and prevalence of newly recognized resistance mechanisms in Turkey. Clin Microbiol Infect 2001; 7:470-478.
13. Gür D, Tutar I, Vardar-Ünlü G, Ünlü M, Özinel MA, Sümerkan B, et al. The in vitro efficacy of isepamicin against Gram-negative hospital isolates. Turkish J Hosp Infect 2001; 5:Suppl 1:19-24.
14. Leblebicioglu H, Gunaydin M, Esen S, Tuncer I, Findik D, Ural O, et al. Surveillance of antimicrobial resistance in gram- negative isolates from intensive care units in Turkey: Analysis of data from the last 5 years. J Chemother 2002; 14 (2): 140-146. (Pubitemid 34454627)
15. Borg MA, van de Sande-Bruinsma N, Scicluna E, de Kraker M, Tiemersma E, Monen J, Grundmann H, on behalf of the ARMed Project members and collaborators. Antimicrobial resistance in invasive strains of Escherichia coli from southern and eastern Mediterranean laboratories. Clin Microbiol Infect 2008; 14: 789-796.
16. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect dis 2006; 6: 629-640. (Pubitemid 44427732)
17. Öktem MA , Gülay Z, Biçmen M, Gür D and the HITIT Project Study Group. qnrA prevalence in extended-spectrum β- lactamase positive Enterobacteriaceae isolates from Turkey. Jpn J Infect Dis 2008; 61: 13-17.
18. Poirel L, Gür D, Minarini L, Arslan U, Nordmann P. on behalf of the Turkish Study Group on ESBL/Qnr relationships. Molecular epidemiology of plasmid-mediated quinolone resistance determinants in extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae isolates from Turkey. 18th ECCMID Poster no: 1527, April 19-22, 2008, Barcelona, Spain.
19. The Turkish Antimicrobial Resistance Study Group, Pfaller MA, Korten V, Jones RN, Doern G. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum β-lactamas in Turkey using the Etest method. Diagn Microbiol Infect Dis 1999; 35: 65-73.
20. Jones RN , Pfaller MA and the MYSTIC Study Group (Europe). Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum β-lactamase in Europe. Clin Microbiol Infect 2003; 9: 708-712.
21. Srinivasan A, Patel JB. Klebsiella pneumoniae carbapenemase-producing organisms: An ounce of prevention really is worth a pound of cure. Infect Control Hosp Epidemiol 2008, 29(12): 1107-1109.
22. Walsh TR. Clinically significant carbapenemases: an update. Curr Opin Infect Dis 2008; 21: 367-371.
23. Qeenan AM, Bush K. Carbapenemases: the versatile β- lactamases. Clin Microbiol Rev 2007; 20: 440-458.
24. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacilliase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22. (Pubitemid 38040171)
25. Aktas Z, Bal C, Midilli K, Poirel L, Nordmann P. First IMP- 1-producing Klebsiella pneumoniae isolate in Turkey. Clin Microbiol Infect 2006; 695-696. (Pubitemid 43842497)
26. Yildirim , Ceyhan M, Gür D, Mugnaioli C, Rossolini GM. First detection of VIM-1 type metallo-beta-lactamase in a multidrug-resistant Klebsiella pneumoniae clinical isolate from Turkey also producing the CTX-M-15 extended-spectrum beta- lactamase. J Chemother 2007; 19(4): 467-468 (Pubitemid 47236530)
27. Aktas Z, Kayacan Bal C, Schneider I, Can B, Midilli K, Bauernfeind A. carbapenem-hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy 2008; 54: 101-106.
28. Gulmez D, Woodford N, Palepou MFI, Mushtaq S, Metan G, Yakupogullari Y, et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48- like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents 2008; 31: 523-526.
29. Ishii Y, Alba J, Kimura S, Yamaguchi K. Evaluation of antimicrobial activity of β-lactam antibiotics by Etest against clinical isolates from 100 medical centers in Japan (2004). Diagn Microbiol Infect Dis 2006; 55(2): 143-148. (Pubitemid 43775919)
30. Fu W, Demei Z, Shi W, Fupin H, Yingyuan Z. The susceptibility of non-fermentative Gram negative bacilli to cefoperazone and sulbactam compared with other bacterial agents. Int J Antimicrob Agents 2003; 22: 444-448.